vimarsana.com

Latest Breaking News On - Globo series - Page 1 : vimarsana.com

OBI Pharma Inc : OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs

TAIPEI, Taiwan, July 05, 2022 (GLOBE NEWSWIRE) OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced discontinuation of the Phase 1/2 Study for OBI 888, a Globo H antibody, upon completion

T ai peiAdagloxad simoleninKostenloser wertpapierhandelMichael changKevin poulosFutures bureauPharma incPharma united states incAdagloxad simolenin vaccineGlobo seriesPrivate securities litigation reform actTaiwan securitiesUnited states

OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

T ai peiUnited statesSan franciscoAdagloxad simoleninKevin poulosApostolia maria tsimberidouMccormick centerAmerican society of clinical oncologyUniversity of texas md anderson cancer centerFutures bureauPharma incPharma united states incFirst in class cancerAmerican societyClinical oncologyAntibody drug conjugate

OBI Pharma Inc : OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3TAIPEI, Taiwan, May 17, 2022 (GLOBE NEWSWIRE) OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer

T ai peiUnited statesSan franciscoAdagloxad simoleninKostenloser wertpapierhandelKevin poulosApostolia maria tsimberidouMccormick centerAmerican society of clinical oncologyUniversity of texas md anderson cancer centerFutures bureauPharma incPharma united states incPoster presentationsFirst in class cancerAmerican society

OBI Pharma, Inc : OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug) and emerging Globo H science. TAIPEI, Taiwan, April 7, 2022 /PRNewswire/ OBI Pharma

T ai peiChung shanT ai chungUnited statesZhanghua xianAdagloxad simoleninChun chung wangLu tzu chenJhih jie yangKevin poulosKostenloser wertpapierhandelJiann shiun laiCheng yen weiChih chan leeSchool of medicineAmerican association of cancer research

OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

/PRNewswire/ OBI Pharma, Inc. (TPEx: 4174) today announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab.

T ai peiChung shanT ai chungUnited statesZhanghua xianAdagloxad simoleninChun chung wangLu tzu chenJhih jie yangKevin poulosJiann shiun laiCheng yen weiChih chan leeSchool of medicineAmerican association of cancer researchPharma united states inc

vimarsana © 2020. All Rights Reserved.